MedTrace Logo

The EPIC Observational Study

NCT00676169 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1248

Last updated 2019-02-01

No results posted yet for this study

Summary

The purpose of this study is to better define risk factors preceding first isolation of Pseudomonas aeruginosa (Pa) from respiratory cultures in cystic fibrosis (CF) lung disease and to better define clinical outcomes associated with acquisition of Pa. This study will also collect and bank DNA samples for current and future studies designed to enhance the understanding of the pathogenesis of CF.

Conditions

Sponsors & Collaborators

  • Cystic Fibrosis Foundation

    collaborator OTHER

  • CF Therapeutics Development Network Coordinating Center

    lead NETWORK

Principal Investigators

  • Margaret Rosenfeld, MD, MPH · Seattle Children's Hospital

  • Ronald L. Gibson, MD, PhD · Seattle Children's Hospital

  • Wayne J. Morgan, MD · University of Arizona Health Sciences Center

Eligibility

Max Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-10-31
Primary Completion
2018-12-31
Completion
2018-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00676169 on ClinicalTrials.gov